Interferons, IFNs, are among the most widely studied and clinically used biopharmaceuticals. Despite their invaluable therapeutic roles, the widespread use of IFNs suffers from some inherent limitations, mainly their relatively short circulation lifespan and their unwanted effects on some non-target tissues. Therefore, both these constraints have become the central focus points for the research efforts on the development of a variety of novel delivery systems for these therapeutic agents with the ultimate goal of improving their therapeutic end-points. Generally, the delivery systems currently under investigation for IFNs can be classified as particulate delivery systems, including micro- and nano-particles, liposomes, minipellets, cellular carriers, and non-particulate delivery systems, including PEGylated IFNs, other chemically conjugated IFNs, immunoconjugated IFNs, and genetically conjugated IFNs. All these strategies and techniques have their own possibilities and limitations, which should be taken into account when considering their clinical application. In this article, currently studied delivery systems/techniques for IFN delivery have been reviewed extensively, with the main focus on the pharmacokinetic consequences of each procedure.

中文翻译：

---

新型干扰素递送系统。

干扰素（IFN）是最广泛研究和临床使用的生物药物之一。尽管其具有非常重要的治疗作用，但IFN的广泛使用仍存在一些固有的局限性，主要是其相对较短的循环寿命以及对某些非靶标组织的有害作用。因此，这两个限制已成为用于开发这些治疗剂的多种新颖的递送系统的研究工作的中心焦点，其最终目的是改善其治疗终点。一般而言，目前正在研究中的IFN递送系统可分为微粒递送系统，包括微粒和纳米颗粒，脂质体，小丸，细胞载体，以及非微粒递送系统，包括PEG化IFN，其他化学结合的IFN，免疫结合的IFN和遗传结合的IFN。所有这些策略和技术都有其自身的可能性和局限性，在考虑其临床应用时应予以考虑。在本文中，已广泛审查了目前研究的用于IFN递送的递送系统/技术，主要侧重于每种方法的药代动力学后果。